Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Harbin Pharmaceutical Group Renmin Tongtai Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

¥6.3

2024-10-29

Market Capitalization

¥3.6 B

2024-10-29

Revenue

¥10.3 B

FY, 2025

CreditSafe Score

?
Score changed on Jun 15, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

CNYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024FY, 2025
Revenue7.0B8.3B7.9B9.3B9.6B10.3B10.0B10.3B
Cost of goods sold6.2B7.3B7.1B8.3B8.7B9.4B9.2B9.5B
Gross profit880.5M995.6M892.2M969.1M888.5M966.0M834.3M821.8M
Gross profit margin, %12.0%11.2%10.5%9.3%9.4%8.4%8.0%
Operating expense total505.4M567.9M613.6M533.9M516.6M513.0M497.1M520.3M
Depreciation and amortization30.8M24.9M24.3M23.2M253.0K17.2M20.2M17.9M
EBITDA375.1M427.7M278.6M435.2M372.0M453.0M337.1M301.5M
EBITDA margin, %5.2%3.5%4.7%3.9%4.4%3.4%2.9%
EBIT367.6M386.1M249.8M408.7M386.3M411.9M303.2M220.3M
EBIT margin, %4.7%3.1%4.4%4.0%4.0%3.0%2.1%
Interest income5.2M4.1M5.7M5.9M13.3M13.9M9.6M4.1M
Interest expense24.4M25.3M30.8M50.3M44.4M27.2M28.3M24.5M
Pre tax profit345.7M361.3M219.7M358.6M345.6M393.4M289.1M189.5M
Income tax expense87.9M94.0M74.7M82.1M81.0M101.1M75.8M55.7M
Net Income257.9M267.3M145.0M276.5M264.5M292.2M213.3M133.8M

Footer menu